Sugar used as 'Trojan Horse' to fight cancer
Researchers in Denmark have discovered a new drug delivery method based on sugar nanocapsules that could be a breakthrough to treat cancer, viral diseases and hereditary disorders.
Archives for November 15, 2006
How to select a suitable aseptic processing CMO
Pharma companies struggling to choose a suitable contract manufacturer to aseptically produce injectable final drug products (FDP) may now have the support they need thanks to a new guide released this week.
Oxford Biomedica presents encouraging data for Parkinson's treatment
Oxford Biomedica has made available preclinical efficacy data, which suggests that gene-based product could have significant efficacy for those suffering from Parkinson's disease when compared to current treatment methods.
More pharma ingredients to be 'made in Taiwan'
International drug firms are increasingly turning to Taiwan for the low-cost made-to-order processing of active pharmaceutical ingredients (APIs), according to the Taiwan External Trade Development Council (TAITRA).
DataLase reveals alternative pharma labelling technique
DataLase has revealed a novel labelling tape that it claims is a cost-effective replacement for print-and-apply labels for outer case secondary pharma packaging.
Oxoid updates contact plate design
Oxoid has introduced a new plate design for the Oxoid range of Contact Plates, which aims to make the microbiological testing of surfaces even easier to store, handle and use.
'Big Pharma' slammed over third-world drug domination
Deprived people are dying because pharmaceutical companies and worldwide governments of rich countries are obstructing the developing world from obtaining affordable medicines, according to a new report.
Researchers identify a new target for painkillers
Scientists, who have been studying the venoms of deadly, sea-dwelling cone snails, believe they have discovered a new target for painkillers, which could represent a new previously unrecognised mechanism for treating pain.
Nautilus and Creabilis demonstrate positive HMGB1 results
Nautilus Biotech and Creabilis Therapeutics have actively demonstrated the increase in biological activity and resistance to proteolysis in vitro of a protein that could play a role in hepatitis B, rheumatoid arthritis, melanoma and sepsis treatments.